Everything below concerns thymosin beta-4 fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-21. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
On 1 June 2020, the United States Pharmacopeia (USP) decided to cancel the proposal to include recombinant technology for endotoxin testing in chapter 85, Bacterial Endotoxins, and start the development of a separate chapter that expands on the use, validation, and comparability of endotoxin tests based on recombinantly derived reagents. A separate guidance-only chapter 1085.1 was proposed by the USP, though comments and feedback published on 11 December 2020 show that pharmaceutical companies and the FDA did not support this chapter and requested compendial status. In response, USP subsequently developed General Chapter <86>, Bacterial Endotoxins Test Using Recombinant Reagents, which provides compendial requirements for endotoxin testing using non-animal-derived reagents such as recombinant factor C (rFC). Chapter <86> became official in USP–NF in May 2025, establishing rFC as a pharmacopeially recognized alternative to the Limulus amebocyte lysate test.
=== Medications === Oral medications like Glipizide that stimulate the pancreas, promoting insulin release (or in some cases, reduce glucose production), are less and less used in cats, and these drugs may be completely ineffective if the pancreas is not working. These drugs have also been shown in some studies to damage the pancreas further or to cause liver damage. Some owners are reluctant to switch from pills to insulin injections, but the fear is unjustified; the difference in cost and convenience is minor (most cats are easier to inject than to pill), and injections are more effective at treating the disease. Bexagliflozin (Bexacat) was approved for medical use in the United States in December 2022. It is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and Drug Administration (FDA) in any animal species. Velagliflozin (Senvelgo), another SGLT2 inhibitor, was approved for medical use in the United States in August 2023 by the FDA. SGLT2 inhibitors are not insulin, nor do they help a diabetic cat's cells use glucose for energy. SGLT2 inhibitors lowers blood glucose levels by excreting glucose through the kidneys. Both medications are prescription only and are given orally (by mouth) once daily. Cats that have been previously treated with long-term insulin therapy, are currently on long-term insulin therapy, or has other underlying health conditions should not take these medications.
64Cu-ATSM (diacetyl-bis(N4-methylthiosemicarbazone)) has been shown to increase the survival time of tumor-bearing animals. Areas of low oxygen retention have been shown to be resistant to external beam radiotherapy because hypoxia reduces the lethal effects of ionizing radiation. 64Cu was believed to kill these cells because of its unique decay properties. In animal models having colorectal tumors with and without induced hypoxia, Cu-ATSM was preferentially taken up by hypoxic cells over normoxic cells. The results demonstrated that this compound increased survival of the tumor bearing hamsters compared with controls.
Sources: en.wikipedia.org
=== Early delivery === Magnesium sulfate was once used as a tocolytic, but meta-analyses have failed to support it as an anti-contraction medication. Usage for prolonged periods (more than five to seven days) may result in health problems for the baby. In those at risk of an early delivery (preterm birth), treatment with magnesium sulfate has a neuroprotective role and decreases the risk of cerebral palsy. The World Health Organization strongly recommends use of magnesium sulfate for women with risk of imminent birth before 32 weeks of gestation. It is unclear if it helps those who are born at term. Guidelines for the use of magnesium sulfate in mothers at risk of preterm labour are not strongly adhered to and the effects of this treatment later in early childhood are unknown.
=== 1976 === January 8: Chinese Premier Zhou Enlai dies of cancer. February: Soviet and Cuban forces install a communist government in Angola. March 24: The National Reorganization Process takes power in Argentina following a successful military coup and launches military action against Argentine-based guerrillas. Jorge Rafael Videla is installed as president. May 4: The Corsican conflict begins, with the aim of an independent Corsican state against the French government by Corsican nationalists. June 29: The Seychelles becomes independent from the UK, as a republic in the Commonwealth of Nations. July 2: Vietnam is officially reunited under a communist regime. July 20: U.S. Military personnel withdraw from Thailand. September 1: Inception of Safari Club. September 9: Death of Mao Zedong. December 4: Insurgency in Aceh begins. Jean-Bédel Bokassa proclaimed himself as Emperor of the Central African Empire.
No law of physics or biology forbids cheap travel and settlement all over the solar system and beyond. But it is impossible to predict how long this will take. Predictions of the dates of future achievements are notoriously fallible. My guess is that the era of cheap unmanned missions will be the next fifty years, and the era of cheap manned missions will start sometime late in the twenty-first century. Any affordable program of manned exploration must be centred in biology, and its time frame tied to the time frame of biotechnology; a hundred years, roughly the time it will take us to learn to grow warm-blooded plants, is probably reasonable.
== Management == The main aim in the treatment of diabetic ketoacidosis is to replace the lost fluids and electrolytes while suppressing the high blood sugars and ketone production with insulin. Admission to an intensive care unit (ICU) or similar high-dependency area or ward for close observation may be necessary.
Sources: en.wikipedia.org
Shaving or trimming (manually or with electric shavers which can be used on pubic hair or body hair) Depilatories (creams or "shaving powders" which chemically dissolve hair) Friction (rough surfaces used to buff away hair)
=== In the West Pacific === Native aluminium has been reported also in cold seeps in the northeastern continental slope of the South China Sea and Chen et al. (2011) have proposed a theory of its origin as resulting by reduction from tetrahydroxoaluminate Al(OH)4− to metallic aluminium by bacteria.
There were 467 injured: 182 civilians, 167 Detroit police officers, 83 Detroit firefighters, 17 National Guard troops, 16 State Police officers, and three U.S. Army soldiers. In the riots, 2,509 stores were looted or burned, 388 families were rendered homeless or displaced, and 412 buildings were burned or damaged enough to be demolished. Dollar losses from arson and looting ranged from $40 million to $80 million.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.